-
Something wrong with this record ?
Adjuvant cardioprotection in cardiac surgery: update
R. Wagner, P. Piler, Z. Gabbasov, J. Maruyama, K. Maruyama, J. Nicovsky, P. Kruzliak,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Free Medical Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2012-12-04
Open Access Digital Library
from 2013-01-01
CINAHL Plus with Full Text (EBSCOhost)
from 2013-01-01
Medline Complete (EBSCOhost)
from 2013-01-01
Health & Medicine (ProQuest)
from 2013
Wiley-Blackwell Open Access Titles
from 2001
ROAD: Directory of Open Access Scholarly Resources
from 2013
PubMed
25215293
DOI
10.1155/2014/808096
Knihovny.cz E-resources
- MeSH
- Adjuvants, Pharmaceutic therapeutic use MeSH
- Ischemic Postconditioning MeSH
- Cardiac Surgical Procedures * adverse effects MeSH
- Cardiotonic Agents therapeutic use MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Cardiac surgery patients are now more risky in terms of age, comorbidities, and the need for complex procedures. It brings about reperfusion injury, which leads to dysfunction and/or loss of part of the myocardium. These groups of patients have a higher incidence of postoperative complications and mortality. One way of augmenting intraoperative myocardial protection is the phenomenon of myocardial conditioning, elicited with brief nonlethal episodes of ischaemia-reperfusion. In addition, drugs are being tested that mimic ischaemic conditioning. Such cardioprotective techniques are mainly focused on reperfusion injury, a complex response of the organism to the restoration of coronary blood flow in ischaemic tissue, which can lead to cell death. Extensive research over the last three decades has revealed the basic mechanisms of reperfusion injury and myocardial conditioning, suggesting its therapeutic potential. But despite the enormous efforts that have been expended in preclinical studies, almost all cardioprotective therapies have failed in the third phase of clinical trials. One reason is that evolutionary young cellular mechanisms of protection against oxygen handling are not very robust. Ischaemic conditioning, which is among these, is also limited by this. At present, the prevailing belief is that such options of treatment exist, but their full employment will not occur until subquestions and methodological issues with the transfer into clinical practice have been resolved.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000625
- 003
- CZ-PrNML
- 005
- 20160122104920.0
- 007
- ta
- 008
- 160108s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2014/808096 $2 doi
- 035 __
- $a (PubMed)25215293
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Wagner, Robert $u Department of Cardiovascular Anesthesiology, Centre of Cardiovascular and Transplant Surgery, Pekarska 53, 656 91 Brno, Czech Republic ; Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic.
- 245 10
- $a Adjuvant cardioprotection in cardiac surgery: update / $c R. Wagner, P. Piler, Z. Gabbasov, J. Maruyama, K. Maruyama, J. Nicovsky, P. Kruzliak,
- 520 9_
- $a Cardiac surgery patients are now more risky in terms of age, comorbidities, and the need for complex procedures. It brings about reperfusion injury, which leads to dysfunction and/or loss of part of the myocardium. These groups of patients have a higher incidence of postoperative complications and mortality. One way of augmenting intraoperative myocardial protection is the phenomenon of myocardial conditioning, elicited with brief nonlethal episodes of ischaemia-reperfusion. In addition, drugs are being tested that mimic ischaemic conditioning. Such cardioprotective techniques are mainly focused on reperfusion injury, a complex response of the organism to the restoration of coronary blood flow in ischaemic tissue, which can lead to cell death. Extensive research over the last three decades has revealed the basic mechanisms of reperfusion injury and myocardial conditioning, suggesting its therapeutic potential. But despite the enormous efforts that have been expended in preclinical studies, almost all cardioprotective therapies have failed in the third phase of clinical trials. One reason is that evolutionary young cellular mechanisms of protection against oxygen handling are not very robust. Ischaemic conditioning, which is among these, is also limited by this. At present, the prevailing belief is that such options of treatment exist, but their full employment will not occur until subquestions and methodological issues with the transfer into clinical practice have been resolved.
- 650 _2
- $a adjuvancia farmaceutická $x terapeutické užití $7 D000277
- 650 12
- $a kardiochirurgické výkony $x škodlivé účinky $7 D006348
- 650 _2
- $a kardiotonika $x terapeutické užití $7 D002316
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ischemický postconditioning $7 D057775
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Piler, Pavel $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic ; Department of Cardiovascular Surgery, Centre of Cardiovascular and Transplant Surgery, Pekarska 53, 656 91 Brno, Czech Republic.
- 700 1_
- $a Gabbasov, Zufar $u Institute of Experimental Cardiology, Russian Cardiology and Research Complex, 3rd Cherepkovskaya 15-A, 12552 Moscow, Russia.
- 700 1_
- $a Maruyama, Junko $u Department of Anesthesiology and Critical Care Medicine, Mie University School of Medicine, 1577 Kurimamachiya-cho, Tsu City, Mie Prefecture 514-8507, Japan ; Department of Clinical Engineering, Suzuka University of Medical Science, 1001-1 Kishiokacho, Suzuka, Mie Prefecture 510-0226, Japan.
- 700 1_
- $a Maruyama, Kazuo $u Department of Anesthesiology and Critical Care Medicine, Mie University School of Medicine, 1577 Kurimamachiya-cho, Tsu City, Mie Prefecture 514-8507, Japan ; Department of Clinical Engineering, Suzuka University of Medical Science, 1001-1 Kishiokacho, Suzuka, Mie Prefecture 510-0226, Japan.
- 700 1_
- $a Nicovsky, Jiri $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic ; Department of Cardiovascular Surgery, Centre of Cardiovascular and Transplant Surgery, Pekarska 53, 656 91 Brno, Czech Republic.
- 700 1_
- $a Kruzliak, Peter $u Department of Cardiovascular Diseases, International Clinical Research Center, St. Anne's University Hospital and Masaryk University, Pekarska 53, 656 91 Brno, Czech Republic.
- 773 0_
- $w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2014, č. - (2014), s. 808096
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25215293 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160122105040 $b ABA008
- 999 __
- $a ok $b bmc $g 1102906 $s 924831
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 2014 $c - $d 808096 $e 20140819 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
- LZP __
- $a Pubmed-20160108